Pharmabiz
 

Pall & New Brunswick enter collaboration on new single-use bioreactors

New YorkWednesday, June 16, 2010, 08:00 Hrs  [IST]

New Brunswick Scientific, an Eppendorf Company and Pall Corporation announced a joint product development and marketing agreement to create and supply new disposable bioreactor systems. The joint effort will build on the capabilities of Pall’s Allegro single-use biocontainer platform and New Brunswick’s CelliGen bioprocess controller, to better serve upstream applications ranging from the process development laboratory to the full-scale cGMP production suite. This partnership combines the historic market strengths of the two companies in upstream biopharmaceutical processing, strengths that have been recently augmented by New Brunswick Scientific’s development of the CelliGen BLU Single-Use Stirred-Tank Bioreactor, and Pall’s acquisition of MicroReactor Technologies and the Micro-24 microbioreactor. According to Mike Sattan, New Brunswick’s vice president marketing, “This is an exciting step forward, as the new system will enable us to offer an even broader range of bioreactor technology options, while we continue to provide a control system with the reliability, ease of use and configurability that our customers have come to expect.” Ken Frank, president Pall Life Sciences Biopharmaceuticals, said, “We are delighted to be able to partner with New Brunswick to extend our Allegro single-use technology to cover the entire range of upstream bioprocessing applications. We believe these new bioreactor systems will provide our customers with greater benefits in operational simplicity, product quality assurance, and process economics.” New Brunswick Scientific’s (NBS) headquarters is based in Edison, New Jersey, USA, with sales and distributor offices located worldwide. Founded in 1946, NBS is a leading manufacturer of innovative equipment for culture growth, detection and storage. Pall Corporation is a filtration, separation and purification leader providing Total Fluid ManagementSM solutions to meet the critical needs of customers in biopharmaceutical; hospital, transfusion and veterinary medicine; energy and alternative energy; electronics; municipal and industrial water; aerospace; transportation and broad industrial markets.

 
[Close]